Clinical Genomicist WorkSpace (CGW)


Streamlined Integrated Workflow

The Clinical Genomicist Workspace (CGW) is our comprehensive environment that will accelerate your ability to offer Next Generation Sequencing-based clinical tests. Our cloud-based single workspace solution seamlessly manages data and clinical workflow for each patient case:

  • Case Accessioning: a clinical genomic test is ordered for a patient either within the CGW or by receipt of an order from upstream medical systems

  • Sequencing: primary data are acquired from sequencers to start the analytical process

  • Analysis: variants are called and annotated using validated pipelines and comprehensive genomic databases

  • Draft Report: medical interpretations and just-in-time curated information from our rapidly expanding medical knowledgebase are processed through a proprietary algorithm, which then produces a report highlighting the most relevant, clinically actionable information

  • Final Report: a fully featured, online editing system allows the medical professional to review, finalize, and sign out a report

  • Integration in Electronic Health Record: signed out report is messaged to the medical record for review by the treating physician

NGS Gateway


The PierianDx NGS Gateway Program allows you to access and customize a range of NGS assays right out of the box utilizing subsets customized from 131 different genes. This program delivers clinically validated Next-Generation Sequencing (NGS) tests for solid tumors, hematopoietic disorders, central nervous system tumors, melanoma and more. The NGS Gateway Program:

  • Enhances your brand by making personalized medicine your competitive advantage

  • Eases transition into fully-integrated NGS lab capabilities

  • No capital outlay to get started

  • Provides speed to market – you focus on your long-term NGS testing strategy while we help you implement today


You can download a complete list of genes tested here.

Test includes total exonic coverage for somatic variants arising in 65 genes and six selected translocations that are clinically actionable in a wide range of adenocarcinomas, squamous cell carcinomas, gliomas, sarcomas and melanomas.

Test includes total exonic coverage for somatic variants arising in 54 genes, including translocations involving MLL/KMT2A, that are clinically actionable in myeloid, lymphoid and mixed lineage leukemias. It also includes genes that can help establish diagnosis and prognosis for pre-leukemic myelodysplastic and myeloproliferative syndromes.

Designed specifically for tumors of the central nervous system, this test includes total exonic coverage for somatic variants arising in 24 genes.

Test includes total exonic coverage for somatic variants arising in 33 genes, including multiple melanoma-specific genes as well as some overlap with the Solid Tumor Gene Set.

Professional Services


PierianDx’s Professional Services ensure that you have everything you need to effectively manage the clinical NGS workflow and can begin case sign-out as rapidly as possible. Our team of genomicists can help you with everything from designing your own NGS testing strategy to final implementation of custom assays. We can help you design and validate your own custom gene panels and pipelines, set up your own CLIA-certified lab, and develop a comprehensive validation plan for each panel. Our professional services allows you to:

  • Accelerate your personalized medicine initiatives

  • Ease transition into fully-integrated NGS lab capabilities

  • Provide flexible engagement services designed around your needs

  • Leverage years of experience and best practices

  • “Our partnership with PierianDx will supply healthcare systems’ in-house labs with a simpler and more integrated workflow. The PierianDx bioinformatics platform and testing services will ultimately speed the delivery of precision care to patients.”

    Jonathan Hirsch, Founder & President of Syapse